Emerging therapeutics for alzheimer's disease

Annual Review of Pharmacology and Toxicology

Volumn 54, Issue , 2014, Pages 381-405

  Chiang, Karen ^a   Koo, Edward H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Amyloid ; Drug development; Tau; Therapeutics

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; TAU PROTEIN;

ALZHEIMER DISEASE; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG DEVELOPMENT; DRUG TARGETING; EXCITOTOXICITY; HUMAN; HYPOTHESIS; IMMUNOTHERAPY; INFLAMMATION; MICROTUBULE; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PALLIATIVE THERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; REVIEW;

ALZHEIMER DISEASE; AMYLOID; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MOLECULAR TARGETED THERAPY; TREATMENT OUTCOME;

EID: 84891871121     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-011613-135932     Document Type: Review

References (195)

1. Huang Y, Mucke L. 2012. Alzheimer mechanisms and therapeutic strategies. Cell 148(6):1204-22
2. Hardy J, Selkoe DJ. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297(5580):353-56
3. Hardy JA, Higgins GA. 1992. Alzheimer's disease: the amyloid cascade hypothesis. Science 256(5054):184-85
4. Haass C, Kaether C, Thinakaran G, Sisodia S. 2012. Trafficking and proteolytic processing of APP. Cold Spring Harb. Perspect. Med. 2(5):a006270
5. Mucke L, Selkoe DJ. 2012. Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harb. Perspect. Med. 2(7):a006338
6. Coric V, Van Dyck CH, Salloway S, Andreasen N, Brody M, et al. 2012. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch. Neurol. 69(11):1430-40
7. Wolfe MS. 2012. γ-Secretase as a target for Alzheimer's disease. Adv. Pharmacol. 64:127-53
8. Vassar R, Kandalepas PC. 2011. The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease. Alzheimer's Res. Ther. 3(3):20
9. Eisai. 2012. Eisai presents first clinical data for BACE inhibitor E2609 at Alzheimer's Association International Conference 2012. News Release, July 19
10. Forman M, Palcza J, Tseng J, Leempoels J, Ramael S, et al. 2012. The novel BACE inhibitor MK-8931 dramatically lowers cerebrospinal fluid Aβpeptides in healthy subjects following single- and multipledose administration. Alzheimer's Dement. 8(4):P704
11. Harrison SM, Harper AJ, Hawkins J, Duddy G, Grau E, et al. 2003. BACE1 (β-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes. Mol. Cell. Neurosci. 24(3):646-55
12. Savonenko AV, Melnikova T, Laird FM, StewartK-A, Price DL, Wong PC. 2008. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc. Natl. Acad. Sci. USA 105(14):5585-90
13. Hu X, Hicks CW, He W, Wong P, Macklin WB, et al. 2006. Bace1 modulates myelination in the central and peripheral nervous system. Nat. Neurosci. 9(12):1520-25
14. Hu X, Zhou X, He W, Yang J, Xiong W, et al. 2010. BACE1 deficiency causes altered neuronal activity and neurodegeneration. J. Neurosci. 30(26):8819-29
15. Rajapaksha TW, Eimer WA, Bozza TC, Vassar R. 2011. The Alzheimer's β-secretase enzyme BACE1 is required for accurate axon guidance of olfactory sensory neurons and normal glomerulus formation in the olfactory bulb. Mol. Neurodegener. 6:88
16. Hitt B, Riordan SM, Kukreja L, Eimer WA, Rajapaksha TW, Vassar R. 2012. β-Site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1)-deficient mice exhibit a close homolog of L1 (CHL1) lossof-function phenotype involving axon guidance defects. J. Biol. Chem. 287(46):38408-25
17. Cai J, Qi X, Kociok N, Skosyrski S, Emilio A, et al. 2012. β-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment. EMBO Mol. Med. 4(9):980-91
18. May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, et al. 2011. Robust central reduction of amyloid-βin humans with an orally available, non-peptidic β-secretase inhibitor. J. Neurosci. 31(46):16507-16
19. Morgan D. 2011. Immunotherapy for Alzheimer's disease. J. Intern. Med. 269(1):54-63
20. Bard F, Fox M, Friedrich S, Seubert P, Schenk D, et al. 2012. Sustained levels of antibodies against Aβ in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice. Exp. Neurol. 238(1):38-43
21. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, et al. 2010. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 9(4):363-72
22. Fändrich M. 2012. Oligomeric intermediates in amyloid formation: structure determination and mechanisms of toxicity. J. Mol. Biol. 421(4-5):427-40
23. Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, et al. 2012. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 11(3):241-49
24. Jawhar S, Wirths O, Bayer TA. 2011. Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease. J. Biol. Chem. 286(45):38825-32
25. Frost JL, Liu B, Kleinschmidt M, Schilling S, Demuth H-U, Lemere CA. 2012. Passive immunization against pyroglutamate-3 amyloid-β reduces plaque burden in Alzheimer-like transgenic mice: a pilot study. Neurodegener. Dis. 10(1-4):265-70
26. Zahs KR, Ashe KH. 2010. "Too much good news"-are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? Trends Neurosci. 33(8):381-89
27. Grundman M, Dibernardo A, Raghavan N, Krams M, Yuen E. 2013. 2012: A watershed year for Alzheimer's disease research. J. Nutr. Health Aging 17(1):51-53
28. Farlow M, Arnold SE, Van Dyck CH, Aisen PS, Snider BJ, et al. 2012. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimer's Dement. 8(4):261-71
29. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, et al. 2010. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9(1):119-28
30. Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, et al. 2013. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12(2):207-16
31. Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, et al. 2012. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367(9):795-804
32. Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, et al. 2012. An effector-reduced anti-β- amyloid (Aβ) antibody with unique Aβbinding properties promotes neuroprotection and glial engulfment of Aβ. J. Neurosci. 32(28):9677-89
33. Atwal JK, Chen Y, Chiu C, Mortensen DL, Meilandt WJ, et al. 2011. A therapeutic antibody targeting BACE1 inhibits amyloid-βproduction in vivo. Sci. Transl. Med. 3(84):84ra43
34. Bach J-P, Dodel R. 2012. Naturally occurring autoantibodies against β-amyloid. Adv. Exp. Med. Biol. 750:91-99
35. Tsakanikas D, Shah K, Flores C, Assuras S, Relkin NR. 2008. Effects of uninterrupted intravenous immunoglobulin treatment of Alzheimer's disease for ninemonths. Alzheimer's Dement. 4(4 Suppl.):T776
36. Baxter Int. Inc. 2013. Baxter announces topline results of Phase III study of immunoglobulin for Alzheimer's disease. News Release, May 7
37. Alzheimer's Assoc. 2013. Additional results from Phase 3 trial of IVIG in Alzheimer's reported at Alzheimer's Association International Conference. News Release, July 16
38. Dodel R, Rominger A, Bartenstein P, Barkhof F, Blennow K, et al. 2013. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebocontrolled, dose-finding trial. Lancet Neurol. 12(3):233-43
39. Orgogozo J-M, Gilman S, Dartigues J-F, Laurent B, Puel M, et al. 2003. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 61(1):46-54
40. Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. 2003. Neuropathology of human Alzheimer disease after immunization with amyloid-βpeptide: a case report. Nat. Med. 9(4):448-52
41. Vellas B, Black R, Thal LJ, Fox NC, Daniels M, et al. 2009. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr. Alzheimer Res. 6(2):144-51
42. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, et al. 2008. Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372(9634):216-23
43. Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, et al. 2012. Safety, tolerability, and antibody response of active Aβimmunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol. 11(7):597-604
44. Cramer PE, Cirrito JR, Wesson DW, Lee CYD, Karlo JC, et al. 2012. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 335(6075):1503-6
45. Fitz NF, Cronican AA, Lefterov I, Koldamova R. 2013. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models." Science 340(6135):924
46. Price AR, Xu G, Siemienski ZB, Smithson LA, Borchelt DR, et al. 2013. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models." Science 340(6135):924
47. Tesseur I, Lo AC, Roberfroid A, Dietvorst S, Van Broeck B, et al. 2013. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models." Science 340(6135):924
48. Veeraraghavalu K, Zhang C, Miller S, Hefendehl JK, Rajapaksha TW, et al. 2013. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models." Science 340(6135):924
49. Carta AR, Pisanu A. 2013. Modulating microglia activity with PPAR-γ agonists: a promising therapy for Parkinson's disease? Neurotox. Res. 23(2):112-23
50. Miller BW, Willett KC, Desilets AR. 2011. Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease. Ann. Pharmacother. 45(11):1416-24
51. Mandelkow E-M, Mandelkow E. 2012. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb. Perspect. Med. 2(7):a006247
52. Gendron TF, Petrucelli L. 2009. The role of tau in neurodegeneration. Mol. Neurodegen. 4(1):13
53. Köpke E, Tung YC, Shaikh S, Alonso AC, Iqbal K, Grundke-Iqbal I. 1993. Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J. Biol. Chem. 268(32):24374-84
54. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. 1992. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42(3 Pt. 1):631-39
55. Gómez-Isla T, Hollister R, West H, Mui S, Growdon JH, et al. 1997. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 41(1):17-24
56. Bierer LM, Hof PR, Purohit DP, Carlin L, Schmeidler J, et al. 1995. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. Arch. Neurol. 52(1):81-88
57. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, et al. 2012. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J. Neuropathol. Exp. Neurol. 71(5):362-81
58. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, et al. 1998. Association of missense and 5′-splicesite mutations in tau with the inherited dementia FTDP-17. Nature 393(6686):702-5
59. Hong M, Zhukareva V, Vogelsberg-Ragaglia V, Wszolek Z, Reed L, et al. 1998. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 282(5395):1914-17
60. Clark LN, Poorkaj P, Wszolek Z, Geschwind DH, Nasreddine ZS, et al. 1998. Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc. Natl. Acad. Sci. USA 95(22):13103-7
61. Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, et al. 1998. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 43(6):815-25
62. Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B. 1998. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. USA 95(13):7737-41
63. Goedert M, Ghetti B, Spillantini MG. 2012. Frontotemporal dementia: implications for understanding Alzheimer disease. Cold Spring Harb. Perspect. Med. 2(2):a006254
64. Ferreira A, Lu Q, Orecchio L, Kosik KS. 1997. Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar A beta. Mol. Cell. Neurosci. 9(3):220-34
65. 2+ elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J. Neurosci. 30(36):11938-50
66. Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ. 2011. Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc. Natl. Acad. Sci. USA 108(14):5819-24
67. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, et al. 2001. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293(5534):1487-91
68. Götz J, Chen F, Van Dorpe J, Nitsch RM. 2001. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Aβ42 fibrils. Science 293(5534):1491-95
69. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, et al. 2003. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron 39(3):409-21
70. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. 2004. Aβimmunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43(3):321-32
71. Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, et al. 2012. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch. Neurol. 69(8):1002-10
72. Coomaraswamy J, Kilger E, Wölfing H, Schäfer C, Kaeser SA, et al. 2010. Modeling familial Danish dementia in mice supports the concept of the amyloid hypothesis of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 107(17):7969-74
73. Karran E, Mercken M, De Strooper B. 2011. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 10(9):698-712
74. Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A. 2002. Tau is essential toβ-amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci. USA 99(9):6364-69
75. Vossel KA, Zhang K, Brodbeck J, Daub AC, Sharma P, et al. 2010. Tau reduction prevents Aβ-induced defects in axonal transport. Science 330(6001):198
76. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, et al. 2007. Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model. Science 316(5825):750-54
77. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, et al. 2010. Dendritic function of tau mediates amyloid-βtoxicity in Alzheimer's disease mouse models. Cell 142(3):387-97
78. Nussbaum JM, Schilling S, Cynis H, Silva A, Swanson E, et al. 2012. Prion-like behaviour and taudependent cytotoxicity of pyroglutamylated amyloid-β. Nature 485(7400):651-55
79. Denk F, Wade-Martins R. 2009. Knock-out and transgenic mouse models of tauopathies. Neurobiol. Aging 30(1):1-13
80. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, et al. 2005. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309(5733):476-81
81. Sydow A, Van der Jeugd A, Zheng F, Ahmed T, Balschun D, et al. 2011. Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenicmice after switching off the toxic Taumutant. J. Neurosci. 31(7):2511-25
82. Phiel CJ, Wilson CA, Lee VM-Y, Klein PS. 2003. GSK-3αregulates production of Alzheimer's disease amyloid-βpeptides. Nature 423(6938):435-39
83. Jo J, Whitcomb DJ, Olsen KM, Kerrigan TL, Lo S-C, et al. 2011. Aβ1-42 inhibition of LTP ismediated by a signaling pathway involving caspase-3, Akt1 and GSK-3β. Nat. Neurosci. 14(5):545-47
84. Hampel H, Ewers M, Bürger K, Annas P, Mörtberg A, et al. 2009. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J. Clin. Psychiatry 70(6):922-31
85. Domínguez JM, Fuertes A, Orozco L, DelMonte-Millán M, Delgado E, Medina M. 2012. Evidence for irreversible inhibition of glycogen synthase kinase-3βby tideglusib. J. Biol. Chem. 287(2):893-904
86. Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF. 2011. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br. J. Psychiatry 198(5):351-56
87. Nunes MA, Viel TA, Buck HS. 2013. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease. Curr. Alzheimer Res. 10(1):104-7
88. De la Monte SM. 2012. Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. Drugs 72(1):49-66
89. Yuzwa SA, Shan X, Macauley MS, Clark T, Skorobogatko Y, et al. 2012. Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat. Chem. Biol. 8(4):393-99
90. Balasubramani A, Rao A. 2013. O-GlcNAcylation and 5-methylcytosine oxidation: an unexpected association between OGT and TETs. Mol. Cell. 49(4):618-19
91. Martin L, Latypova X, Wilson CM, Magnaudeix A, PerrinM-L, Terro F. 2013. Tau protein phosphatases in Alzheimer's disease: the leading role of PP2A. Ageing Res. Rev. 12(1):39-49
92. Kickstein E, Krauss S, Thornhill P, Rutschow D, Zeller R, et al. 2010. Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc. Natl. Acad. Sci. USA 107(50):21830-35
93. Wang J, Gallagher D, DeVito LM, Cancino GI, Tsui D, et al. 2012. Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation. Cell Stem Cell 11(1):23-35
94. Mairet-Coello G, Courchet J, Pieraut S, Courchet V, Maximov A, et al. 2013. The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Aβoligomers through tau phosphorylation. Neuron 78(1):94-108
95. Vingtdeux V, Giliberto L, Zhao H, Chandakkar P, Wu Q, et al. 2010. AMP-activated protein kinase signaling activation by resveratrolmodulates amyloid-βpeptidemetabolism. J. Biol. Chem. 285(12):9100-13
96. Van Eersel J, Ke YD, Liu X, Delerue F, Kril JJ, et al. 2010. Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. Proc. Natl. Acad. Sci. USA 107(31):13888-93
97. Corcoran NM, Martin D, Hutter-Paier B, Windisch M, Nguyen T, et al. 2010. Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer's disease model. J. Clin. Neurosci. 17(8):1025-33
98. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. 2007. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci. 27(34):9115-29
99. Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H. 2010. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp. Neurol. 224(2):472-85
100. Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean M-E, et al. 2012. Targeting phospho-Ser422 by active Tau immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr. Alzheimer Res. 9(4):397-405
101. Bi M, Ittner A, Ke YD, Götz J, Ittner LM. 2011. Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS ONE 6(12):e26860
102. Boutajangout A, Quartermain D, Sigurdsson EM. 2010. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J. Neurosci. 30(49):16559-66
103. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM. 2011. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J. Neurochem. 118(4):658-67
104. Chai X, Wu S, Murray TK, Kinley R, Cella CV, et al. 2011. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J. Biol. Chem. 286(39):34457-67
105. Guo K, Li J, Tang JP, Tan CPB, Hong CW, et al. 2011. Targeting intracellular oncoproteins with antibody therapy or vaccination. Sci. Transl. Med. 3(99):99ra85
106. Dao T, Yan S, Veomett N, Pankov D, Zhou L, et al. 2013. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci. Transl. Med. 5(176):176ra33
107. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, et al. 2005. Effects ofα-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46(6):857-68
108. De Calignon A, Polydoro M, Suárez-Calvet M, William C, Adamowicz DH, et al. 2012. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73(4):685-97
109. Liu L, Drouet V, Wu JW, Witter MP, Small SA, et al. 2012. Trans-synaptic spread of tau pathology in vivo. PLoS ONE 7(2):e31302
110. Braak H, Braak E. 1991. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82(4):239-59
111. Frost B, Jacks RL, Diamond MI. 2009. Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 284(19):12845-52
112. Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI. 2012. Trans-cellular propagation of Tau aggregation by fibrillar species. J. Biol. Chem. 287(23):19440-51
113. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, et al. 2009. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 11(7):909-13
114. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Kiritoshi T, et al. 2012. Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci. Rep. 2:700
115. Pooler AM, Phillips EC, Lau DHW, Noble W, Hanger DP. 2013. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 14(4):389-94
116. Saman S, Kim W, Raya M, Visnick Y, Miro S, et al. 2012. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J. Biol. Chem. 287(6):3842-49
117. Chai X, Dage JL, Citron M. 2012. Constitutive secretion of tau protein by an unconventional mechanism. Neurobiol. Dis. 48(3):356-66
118. Wu JW, Herman M, Liu L, Simoes S, Acker CM, et al. 2013. Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J. Biol. Chem. 288(3):1856-70
119. Schirmer RH, Adler H, Pickhardt M, Mandelkow E. 2011. "Lest we forget you-methylene blue..." Neurobiol. Aging 32(12):2325.e7-16
120. Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR. 1996. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc. Natl. Acad. Sci. USA 93(20):11213-18
121. Wischik CM, Bentham P, Wischik DJ, Seng KM. 2008. Tau aggregation inhibitor (TAI) therapy with remberTM arrests disease progression in mild andmoderate Alzheimer's disease over 50 weeks. Alzheimer's Dement. 4(4 Suppl.):T167
122. O'Leary JC, Li Q, Marinec P, Blair LJ, Congdon EE, et al. 2010. Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. Mol. Neurodegener. 5:45
123. Medina DX, Caccamo A, Oddo S. 2011. Methylene blue reduces Aβlevels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol. 21(2):140-49
124. Taniguchi S, Suzuki N, Masuda M, Hisanaga S, Iwatsubo T, et al. 2005. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J. Biol. Chem. 280(9):7614-23
125. Jinwal UK, Miyata Y, Koren J, Jones JR, Trotter JH, et al. 2009. Chemical manipulation of Hsp70 ATPase activity regulates tau stability. J. Neurosci. 29(39):12079-88
126. Wen Y, Li W, Poteet EC, Xie L, Tan C, et al. 2011. Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. J. Biol. Chem. 286(18):16504-15
127. Eckert GP, Renner K, Eckert SH, Eckmann J, Hagl S, et al. 2012. Mitochondrial dysfunction-a pharmacological target in Alzheimer's disease. Mol. Neurobiol. 46(1):136-50
128. Lin A-L, Poteet E, Du F, Gourav RC, Liu R, et al. 2012. Methylene blue as a cerebral metabolic and hemodynamic enhancer. PLoS ONE 7(10):e46585
129. Akoury E, Pickhardt M, Gajda M, Biernat J, Mandelkow E, Zweckstetter M. 2013. Mechanistic basis of phenothiazine-driven inhibition of Tau aggregation. Angew. Chem. Int. Ed. Engl. 52(12):3511-15
130. Amatniek JC, Hauser WA, DelCastillo-Castaneda C, Jacobs DM, Marder K, et al. 2006. Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia 47(5):867-72
131. Irizarry MC, Jin S, He F, Emond JA, Raman R, et al. 2012. Incidence of new-onset seizures in mild to moderate Alzheimer disease. Arch. Neurol. 69(3):368-72
132. Minkeviciene R, Rheims S, Dobszay MB, Zilberter M, Hartikainen J, et al. 2009. Amyloid β-induced neuronal hyperexcitability triggers progressive epilepsy. J. Neurosci. 29(11):3453-62
133. Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, et al. 2007. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits inmousemodels of Alzheimer's disease. Neuron 55(5):697-711
134. Palop JJ, Mucke L. 2009. Epilepsy and cognitive impairments in Alzheimer disease. Arch. Neurol. 66(4):435-40
135. Palop JJ, Mucke L. 2010. Amyloid-β-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat. Neurosci. 13(7):812-18
136. Götz J, Ittner LM, Kins S. 2006. Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease? J. Neurochem. 98(4):993-1006
137. Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, et al. 2011. Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J. Neurosci. 31(2):700-11
138. Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, et al. 2012. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc. Natl. Acad. Sci. USA 109(42):E2895-903
139. Lee G-H, Kim B-M, Kang JK, Lee S-A. 2013. Loss of the initial efficacy of levetiracetam in patients with refractory epilepsy. Seizure 22(3):185-88
140. Bakker A, Krauss GL, Albert MS, Speck CL, Jones LR, et al. 2012. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron 74(3):467-74
141. Lee VM-Y, Brunden KR, Hutton M, Trojanowski JQ. 2011. Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harb. Perspect. Med. 1(1):a006437
142. Morris M, Maeda S, Vossel K, Mucke L. 2011. The many faces of tau. Neuron 70(3):410-26
143. Allon Therapeutics Inc. 2012. Allon announces PSP clinical trial results. News Release, Dec. 18
144. Barten DM, Fanara P, Andorfer C, Hoque N, Wong PYA, et al. 2012. Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubulestabilizing agent BMS-241027. J. Neurosci. 32(21):7137-45
145. Zhang B, Carroll J, Trojanowski JQ, Yao Y, Iba M, et al. 2012. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J. Neurosci. 32(11):3601-11
146. Wyss-Coray T. 2006. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat. Med. 12(9):1005-15
147. McGeer PL, Schulzer M, McGeer EG. 1996. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47(2):425-32
148. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, et al. 2000. Inflammation and Alzheimer's disease. Neurobiol. Aging 21(3):383-421
149. Krstic D, Knuesel I. 2013. Deciphering the mechanism underlying late-onset Alzheimer disease. Nat. Rev. Neurol. 9(1):25-34
150. Lee DC, Rizer J, Hunt JB, Selenica M-LB, Gordon MN, Morgan D. 2013. Review: experimental manipulations of microglia in mouse models of Alzheimer's pathology: activation reduces amyloid but hastens tau pathology. Neuropathol. Appl. Neurobiol. 39(1):69-85
151. Aguzzi A, Barres BA, Bennett ML. 2013. Microglia: scapegoat, saboteur, or something else? Science 339(6116):156-61
152. Aisen PS. 2002. The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurol. 1(5):279-84
153. Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JCS, et al. 2008. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch. Neurol. 65(7):896-905
154. Lyketsos CG, Breitner JCS, Green RC, Martin BK, Meinert C, et al. 2007. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 68(21):1800-8
155. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, et al. 2001. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 414(6860):212-16
156. Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, et al. 2009. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302(23):2557-64
157. Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Logroscino G, et al. 2011. Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation. Curr. Med. Chem. 18(35):5430-47
158. Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, et al. 2011. Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimer's Dement. 7(4):402-11
159. Piette F, Belmin J, Vincent H, Schmidt N, Pariel S, et al. 2011. Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial. Alzheimer's Res. Ther. 3(2):16
160. Imbimbo BP, Hutter-Paier B, Villetti G, Facchinetti F, Cencacchi V, et al. 2009. CHF5074, a novel γ-secretase modulator, attenuates brain β-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. Br. J. Pharmacol. 156(6):982-93
161. Sivilia S, Lorenzini L, Giulani A, Gusciglio M, Fernandez M, et al. 2013. Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice. BMC Neurosci. 14:44
162. Cere Spir Inc. 2013. Cere Spir Incorporated is pleased with positive interim Phase 2 results for CHF 5074 in patients with mild cognitive impairment, presented by Chiesi at the AAIC 2013 Meeting in Boston. News Release, July 26
163. Ross J, Sharma S, Winston J, Nunez M, Bottini G, et al. 2013. CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-week, double-blind, placebo-controlled study. Curr. Alzheimer Res. 10(7):742-53
164. Vom Berg J, Prokop S, Miller KR, Obst J, Kälin RE, et al. 2012. Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat. Med. 18(12):1812-19
165. Yiannopoulou KG, Papageorgiou SG. 2013. Current and future treatments for Alzheimer's disease. Ther. Adv. Neurol. Disord. 6(1):19-33
166. Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM. 2013. Monetary costs of dementia in the United States. N. Engl. J. Med. 368(14):1326-34
167. Alzheimer's Assoc. 2010. Changing the Trajectory of Alzheimer's Disease: A National Imperative. Chicago: Alzheimer's Assoc. http://www.alz.org/documents- custom/trajectory.pdf
168. Mevel K, Chételat G, Eustache F, Desgranges B. 2011. The default mode network in healthy aging and Alzheimer's disease. Int. J. Alzheimer's Dis. 2011:535816
169. Buckner RL, Andrews-Hanna JR, Schacter DL. 2008. The brain's default network: anatomy, function, and relevance to disease. Ann. N.Y. Acad. Sci. 1124:1-38
170. Sheline YI, Morris JC, Snyder AZ, Price JL, Yan Z, et al. 2010. APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Aβ42. J. Neurosci. 30(50):17035-40
171. Lyketsos CG, Targum SD, Pendergrass JC, Lozano AM. 2012. Deep brain stimulation: a novel strategy for treating Alzheimer's disease. Innov. Clin. Neurosci. 9(11-12):10-17
172. Arrieta-Cruz I, Pavlides C, Pasinetti GM. 2010. Deep brain stimulation in midline thalamic region facilitates synaptic transmission and short-termmemory in a mousemodel of Alzheimer's disease. Transl. Neurosci. 1(3):188-94
173. Stone SSD, Teixeira CM, Devito LM, Zaslavsky K, Josselyn SA, et al. 2011. Stimulation of entorhinal cortex promotes adult neurogenesis and facilitates spatial memory. J. Neurosci. 31(38):13469-84
174. Laxton AW, Tang-Wai DF, McAndrews MP, Zumsteg D, Wennberg R, et al. 2010. A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease. Ann. Neurol. 68(4):521-34
175. Smith GS, Laxton AW, Tang-Wai DF, McAndrews MP, Diaconescu AO, et al. 2012. Increased cerebral metabolism after 1 year of deep brain stimulation in Alzheimer disease. Arch. Neurol. 69(9):1141-48
176. Stern Y. 2012. Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol. 11(11):1006-12
177. Lazarov O, Mattson MP, Peterson DA, Pimplikar SW, Van Praag H. 2010. When neurogenesis encounters aging and disease. Trends Neurosci. 33(12):569-79
178. 6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease. Neurotherapeutics 5(3):458-69
179. 6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int. J. Neuropsychopharmacol. 13(8):1021-33
180. EnVivo Pharmaceuticals. 2012. EnVivo Pharmaceuticals announces statistically significant improvement in cognition and clinical function in Phase 2b clinical trial in Alzheimer's disease. News Release, July 18
181. Levin ED. 2002. Nicotinic receptor subtypes and cognitive function. J. Neurobiol. 53(4):633-40
182. Marien MR, Colpaert FC, Rosenquist AC. 2004. Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Res. Brain Res. Rev. 45(1):38-78
183. Orion Corp. 2013. Orion Corporation presented promising Phase II data for new Alzheimer's disease drug at AAN Annual Meeting. News Release, Mar. 21
184. Kozauer N, Katz R. 2013. Regulatory innovation and drug development for early-stage Alzheimer's disease. N. Engl. J. Med. 368:1169-71
185. Martenyi F, Dean RA, Lowe S, Nakano M, Monk S, et al. 2012. BACE inhibitor LY2886721 safety and central and peripheral PK and PD in healthy subjects (HSs). Alzheimer's Dement. 8(4 Suppl.):P583-84
186. Eli Lilly and Co. 2013. Lilly voluntarily terminates Phase II study for LY2886721, a beta secretase inhibitor, being investigated as a treatment for Alzheimer's disease. News Release, June 13
187. Doody RS. 2012. Phase 3 studies of solanezumab for mild to moderate Alzheimer's disease. Presented at Am. Neurol. Assoc. 2012 Annu. Meet., Oct. 7-9, Boston
188. Hake A, Siemers E, Carlson C, Estergard W, Sundell K, et al. 2013. Efficacy and safety of intravenous solanezumab in patients with mild to moderate Alzheimer's disease: results of two phase 3 studies. Neurology 80(Meet. Abstr. 1):S24-006. http://www.neurology.org/cgi/content/meeting-abstract/80/1- MeetingAbstracts/S24.006-abstract/80/1-MeetingAbstracts/S24.006
189. Grimm J. 2012. Immunotherapy with recombinant human-derived antibodies. Presented at 8th Int. Winter Conf. Alzheimer's Dis. Program, Dec. 7-10, Zuers, Austria
190. Noscira. 2012. Noscira announces results from ARGO Phase IIb trial of tideglusib for the treatment of Alzheimer's disease. News Release, Oct. 11
191. Rabey JM, Dobronevsky E, Aichenbaum S, Gonen O, Marton RG, Khaigrekht M. 2013. Repetitive transcranial magnetic stimulation combined with cognitive training is a safe and effective modality for the treatment of Alzheimer's disease: a randomized, double-blind study. J. Neural Transm. 120(5):813-19
192. Boggio PS, Ferrucci R, Mameli F, Martins D, Martins O, et al. 2012. Prolonged visual memory enhancement after direct current stimulation in Alzheimer's disease. Brain Stimul. 5(3):223-30
193. Lundbeck. 2012. Lundbeck's Lu AE58054 meets primary endpoint in large placebo-controlled clinical proof of concept study in people with Alzheimer's disease. News Release, May 29
194. Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, et al. 2009. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging 30(11):1728-36
195. Kile S, Au W, Parise C, Low R. 2013. Initial findings of a randomized double-blinded placebo-controlled study of intravenous immunoglobulin in mild cognitive impairment due to Alzheimer disease. Neurology 80(Meet. Abstr. 1):P01-013. http://www.neurology.org/cgi/content/meeting-abstract/80/1- MeetingAbstracts/P01.013